Stem Cell Therapy Market Report 2026

The stem cell therapy market size has grown rapidly in recent years. It will grow from $9.26 billion in 2025 to $10.51 billion in 2026 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to limited effectiveness of conventional treatments, increasing prevalence of chronic and degenerative diseases, growth in academic and clinical research funding, early success of bone marrow transplantation, rising awareness of regenerative medicine.

The stem cell therapy market size is expected to see rapid growth in the next few years. It will grow to $16.12 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to expanding therapeutic applications beyond hematology, improving clinical outcomes through combination therapies, rising investment from biotechnology firms, increasing acceptance by regulatory authorities, growing demand for personalized medicine. Major trends in the forecast period include expansion of cell-based regenerative therapies, rising adoption of autologous stem cell procedures, increasing clinical trials for multisystem disorders, advancements in stem cell banking infrastructure, growing integration of stem cell therapy in oncology.

The expanding adoption of personalized medicine is anticipated to drive the growth of the stem cell therapy market in the coming years. Personalized medicine, often referred to as precision medicine, is a healthcare approach that considers individual differences in genetics, environment, and lifestyle when designing treatment strategies. By customizing stem cell therapies according to a patient’s specific genetic and clinical profile, personalized medicine improves therapeutic outcomes, minimizes side effects, and emphasizes patient safety and well-being. This patient-focused strategy, along with accurate patient selection, more efficient clinical trials, and broader market reach, is expected to increase the attractiveness of stem cell therapies and support market expansion. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022. These approvals included seven cancer therapies and three treatments targeting other diseases and conditions. Therefore, the growing advancement of personalized medicine is contributing significantly to the expansion of the stem cell therapy market.

Major companies operating in the stem cell therapy market are concentrating on the development of advanced automated manufacturing solutions, such as end-to-end microfluidic-based cell processing platforms, to enhance scalability, consistency, and production efficiency. These platforms are fully integrated automated systems that leverage microfluidic technology to carry out all essential stages of cell therapy manufacturing within a single, closed, precise, and scalable framework. For instance, in March 2025, Limula SA, a Switzerland-based cell therapy technology company, introduced LimONE, a system designed to simplify the manufacturing of both autologous and allogeneic cell therapies. LimONE integrates automated cell enrichment, bioprocessing, and final formulation into one modular unit, allowing for standardized, scalable, and cost-effective cell therapy production. By reducing process variability and enabling continuous, closed-system manufacturing, LimONE improves production reliability and supports wider clinical and commercial adoption of stem cell and other cell-based therapies.

In April 2024, Century Therapeutics Inc., a US-based biotechnology company, acquired Clade Therapeutics Inc. for an undisclosed sum. This acquisition aims to enhance Century Therapeutics’ development pipeline by incorporating Clade’s advanced stem cell engineering technologies, accelerating the creation of next-generation allogeneic therapies, and broadening its capabilities within immuno-oncology. Clade Therapeutics Inc. is a US-based biotechnology company specializing in the development of engineered stem cell-derived therapeutic solutions.

Major companies operating in the stem cell therapy market are Fujifilm Holding Corporation, Thermo Fisher Scientific Inc., Takara Bio Inc., MEDIPOST Co. Ltd., Astellas Pharma Inc., Catalent Inc., Pharmicell Co. Ltd., JCR Pharmaceuticals Co. Ltd., Stemedica Cell Technologies Inc., Pluristem Technologies Ltd, Becton Dickinson Private Limited, Stem Cell Technologies India Pvt. Ltd, Cordlife India Pvt. Ltd, Lifecell International Pvt. Ltd, Stemcyte India Therapeutics Private Limited, Stempeutics Research Private Limited, Anterogen Co. Ltd, Tonghua Dongbao Pharmaceutical Co, China Biologic Products Holdings Inc, Cellerix, Cellgenix, NSgene, Tigenix, Renuron Group, Smart Cells, Genenta Science, Amsterdam Molecular Therapeutics (AMT), Ark Therapeutics, Arthrogen Bv, Diamyd Medical Ab, Oxford Biomedica, Transgene, Oncoarendi Therapeutics, Celon Pharma, Osiris Therapeutics, Capricortherapeutics, Cellular Dynamics, Discgenics, Takeda Pharmaceuticals, Kolon Tissue Gene, Athersys, Cyro-Cell International, Geron Corporation, Mesoblast Ltd, Astrom Biosciences Inc, Invitrogen, Cytori Therapeutics Inc, Nuvasive Inc, Aldagen Inc, Caladrius Biosciences Inc, Biogen Sa, Gamida Cell Ltd, Hisun Pharma, Novartis.

North America was the largest region in the stem cell therapy market in 2025. The Middle East is expected to be the fastest-growing region in the global stem cell therapy market during the forecast period. The regions covered in the stem cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the stem cell therapy market by increasing the cost of importing specialized laboratory equipment, cell culture media, and cryopreservation systems used across research and clinical settings. Higher input costs have particularly impacted allogeneic stem cell therapy providers, research centers, and hospitals in regions reliant on cross-border supply chains such as Asia-Pacific and parts of Europe. These trade barriers have slowed project timelines and raised treatment costs, affecting affordability and scalability. However, tariffs have also encouraged local manufacturing, domestic sourcing of biological materials, and regional partnerships, supporting long-term supply chain resilience and localized innovation.

The stem cell therapy market research report is one of a series of new reports that provides stem cell therapy market statistics, including stem cell therapy industry global market size, regional shares, competitors with a stem cell therapy market share, detailed stem cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell therapy industry. This stem cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cell therapy is a type of regenerative medicine that utilizes stem cells or substances derived from them to activate the body’s inherent healing mechanisms in tissues that are damaged, diseased, or injured. It represents an advancement beyond traditional organ transplantation by aiming to replace the need for limited donor organs with cellular-based treatments.

The primary forms of stem cell therapy include allogeneic and autologous stem cell therapy. Allogeneic stem cell transplantation involves introducing stem cells from a healthy donor into a patient’s body, typically following intensive chemotherapy or radiation treatment. These cells can be obtained from several sources, such as adult stem cells, induced pluripotent stem cells, and embryonic stem cells, and are applied in the treatment of conditions including musculoskeletal diseases, wounds and injuries, cancer, autoimmune disorders, and more. Such therapies are administered through hospitals and specialized clinics.

The stem cell therapy market includes revenues earned by entities by hematopoietic stem cells, skin stem cells, neural stem cells, and mesenchymal stem cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.